Novartis: Pipeline Progress And Buyback Drive Upside

Novartis delivered robust Q2 2025 results, reporting a 24% increase in net income to $4.0 billion and a 37% rise in free cash flow to $6.3 billion, propelled by strong performance from key growth drivers like Kisqali and Pluvicto. Despite ongoing concerns regarding Entresto generics and potential US tariffs (which spare pharmaceuticals), the company raised its guidance, announced a $10 billion share buyback program through 2027, and highlighted positive late-stage trial readouts alongside a significant $23 billion U.S. investment plan. This solid performance and strategic outlook reinforce analysts' continued positive stance, leading to a reiterated 'buy' rating with a $130.5 target price.

Analysis

Novartis demonstrated robust financial health in its Q2 2025 results, with net income rising 24% year-over-year to $4.0 billion and core operating income growing 21% to $5.9 billion. This performance, driven by strong momentum from key drugs Kisqali, which saw 100% turnover growth in the US, and Pluvicto, offset headwinds from weaker Cosentyx sales and faster-than-expected erosion of legacy products. Despite top-line sales of $14.05 billion coming in marginally below consensus, the firm generated an impressive $6.3 billion in free cash flow, a 37% YoY increase, while still investing $2.7 billion in R&D. Strategically, the company is proactively managing near-term risks, such as the entry of Entresto generics, by advancing a promising late-stage pipeline including Pluvicto's label expansion and potential blockbusters like Leqvio. External threats from US tariffs on Swiss goods appear contained, as pharmaceuticals are currently exempt and Novartis is strengthening its US ties with a planned $23 billion investment. Management's confidence is further underscored by an upgraded full-year guidance and the initiation of a $10 billion share buyback program, which is expected to boost EPS by 4-5%.

Key Decisions for Investors

• Investors should weigh the strong fundamental momentum, evidenced by a 37% rise in FCF and an increased corporate guidance, against the valuation, as the stock has already seen double-digit gains and reached the prior price objective.
• It is critical to monitor the pace of sales erosion from Entresto generics, as this remains the most significant headwind and a key variable in near-term earnings forecasts.
• The success of the late-stage pipeline, particularly the commercial ramp-up of Pluvicto and Leqvio, should be viewed as the primary catalyst for offsetting generic pressures and validating the company's long-term pivot to innovative medicines.
• Consider the $10 billion share buyback as a significant source of shareholder return and EPS support through 2027, but remain aware of execution risks including potential pipeline failures, leadership transition with the CFO's retirement, and any unfavorable shifts in US trade or drug pricing policy.